Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer

Yuko Matsubara; Keiichiro Nakamura; Hirofumi Matsuoka; Chikako Ogawa; Hisashi Masuyama

doi:10.3892/mco.2019.1912

Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer

Yuko Matsubara, Keiichiro Nakamura, Hirofumi Matsuoka, Chikako Ogawa, Hisashi Masuyama

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.

Original language	English
Pages (from-to)	376-382
Number of pages	7
Journal	Molecular and Clinical Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.3892/mco.2019.1912
Publication status	Published - Oct 2019

Keywords

Low skeletal muscle mass
Ovarian cancer
Prognostic factor
Psoas area
Psoas major volume
Skeletal muscle area

ASJC Scopus subject areas

Cancer Research
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3892/mco.2019.1912

Cite this

@article{0cf0941d37284006a1023659d1caa8f0,

title = "Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer",

abstract = "Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.",

keywords = "Low skeletal muscle mass, Ovarian cancer, Prognostic factor, Psoas area, Psoas major volume, Skeletal muscle area",

author = "Yuko Matsubara and Keiichiro Nakamura and Hirofumi Matsuoka and Chikako Ogawa and Hisashi Masuyama",

year = "2019",

month = oct,

doi = "10.3892/mco.2019.1912",

language = "English",

volume = "11",

pages = "376--382",

journal = "Molecular and Clinical Oncology",

issn = "2049-9450",

publisher = "Spandidos Publications UK",

number = "4",

}

TY - JOUR

T1 - Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer

AU - Matsubara, Yuko

AU - Nakamura, Keiichiro

AU - Matsuoka, Hirofumi

AU - Ogawa, Chikako

AU - Masuyama, Hisashi

PY - 2019/10

Y1 - 2019/10

N2 - Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.

AB - Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.

KW - Low skeletal muscle mass

KW - Ovarian cancer

KW - Prognostic factor

KW - Psoas area

KW - Psoas major volume

KW - Skeletal muscle area

UR - http://www.scopus.com/inward/record.url?scp=85073392966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073392966&partnerID=8YFLogxK

U2 - 10.3892/mco.2019.1912

DO - 10.3892/mco.2019.1912

M3 - Article

AN - SCOPUS:85073392966

VL - 11

SP - 376

EP - 382

JO - Molecular and Clinical Oncology

JF - Molecular and Clinical Oncology

SN - 2049-9450

IS - 4

ER -

Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this